Transforming growth factor-beta-1

Drug Profile

Transforming growth factor-beta-1

Alternative Names: TGF-beta-1; Transforming growth factor-beta

Latest Information Update: 14 Nov 2006

Price : $50

At a glance

  • Originator Genentech
  • Developer Genentech; National Cancer Institute (USA)
  • Class Antineoplastics; Antivirals; Growth factors; Nootropics; Transforming growth factors
  • Mechanism of Action Transforming growth factor beta1 stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No

Highest Development Phases

  • Discontinued Alzheimer's disease; Atherosclerosis; Cancer; Skin disorders; Systemic lupus erythematosus

Most Recent Events

  • 17 Sep 2001 A study has been added to the Alzheimer's Disease pharmacodynamics section
  • 14 Jan 1997 Preclinical development for Skin disorders in USA (Unknown route)
  • 04 Dec 1996 Preclinical development for Systemic lupus erythematosus (Unknown route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top